BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 31533857)

  • 1. Preoperative albumin-to-fibrinogen ratio predicts chemotherapy resistance and prognosis in patients with advanced epithelial ovarian cancer.
    Yu W; Ye Z; Fang X; Jiang X; Jiang Y
    J Ovarian Res; 2019 Sep; 12(1):88. PubMed ID: 31533857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.
    Ying J; Zhou D; Gu T; Huang J; Liu H
    BMC Cancer; 2019 Mar; 19(1):288. PubMed ID: 30925910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The relationship of preoperativelymphocyte-monocyte ratio and the clinicopathological characteristics and prognosis of patients with epithelial ovarian cancer].
    Yang HM; Lou G
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):676-680. PubMed ID: 28926896
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum CA125 levels predict outcome of interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Zhang D; Jiang YX; Luo SJ; Zhou R; Jiang QX; Linghu H
    Clin Chim Acta; 2018 Sep; 484():32-35. PubMed ID: 29702068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
    Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
    J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer.
    Merlo S; Besic N; Drmota E; Kovacevic N
    Radiol Oncol; 2021 Aug; 55(3):341-346. PubMed ID: 33675192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma.
    Chen W; Shan B; Zhou S; Yang H; Ye S
    BMC Cancer; 2022 Jan; 22(1):92. PubMed ID: 35062908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C; Yao K; Li L; Yi T; Zhao X
    Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Significance of CA125 Dynamic Change for Progression Free Survival in Patients with Epithelial Ovarian Carcinoma.
    Li Z; Yin H; Ren M; Shen Y
    Med Sci Monit; 2020 Sep; 26():e925051. PubMed ID: 32908118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of CA-125 re-elevation after interval debulking surgery in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.
    Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
    Eur J Surg Oncol; 2019 Apr; 45(4):644-649. PubMed ID: 30337203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer.
    Timmermans M; Zwakman N; Sonke GS; Van de Vijver KK; Duk MJ; van der Aa MA; Kruitwagen RF
    Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():364-369. PubMed ID: 31400565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
    Feng Z; Wen H; Bi R; Duan Y; Yang W; Wu X
    BMC Cancer; 2016 Jan; 16():43. PubMed ID: 26817451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of the controlling nutritional status (CONUT) score in epithelial ovarian cancer.
    Li Y; Zhang C; Ji R; Lu H; Zhang W; Li LL; Liu R; Qian H; He A
    Int J Gynecol Cancer; 2020 Jan; 30(1):74-82. PubMed ID: 31822507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of pretreatment albumin-to-fibrinogen ratio in small cell lung cancer patients receiving first-line platinum-based chemotherapy.
    Li Q; Li L; Wang Y; Xu C; Zou J
    Heliyon; 2023 Sep; 9(9):e19225. PubMed ID: 37662747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic Value of Pre-treatment Albumin/Fibrinogen Ratio in Patients with Diffuse Large B-cell Lymphoma].
    Deng H; Zhang L; Wang HY; Huang MJ; Wei J; Zou XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):762-768. PubMed ID: 37356937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
    Zhang J; Liu N; Zhang A; Bao X
    J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications.
    Chen W; Zhong S; Shan B; Zhou S; Wu X; Yang H; Ye S
    J Ovarian Res; 2020 Aug; 13(1):89. PubMed ID: 32771026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer.
    Zhao D; Wang X; Zhang W
    BMC Cancer; 2018 Mar; 18(1):328. PubMed ID: 29580231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.